BCPC at a glance
BALCHEM CORP (BCPC, SEC CIK 9326) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on July 31, 2026 and Form 4 insider filings as recently as February 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BALCHEM CORP (BCPC) reported revenue of $1.0 billion (up 8.8% from FY2024) and net income of $154.8 million. Diluted EPS was $4.75.
- As of June 30, 2026, 36 institutional investment managers tracked by SignalX reported holding BALCHEM CORP (BCPC) shares worth $2.6 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.0B
- +8.8% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 36 funds
- $2.6B · −1 vs prior quarter
- Latest 8-K
- Jul 31, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Specialty chemicals and ingredients for health, nutrition, and performance markets
- 2026 emphasis on regulatory impact of EPA's EtO Interim Decision affecting sterilization products and applications
- Strategic focus on stakeholder engagement to influence EPA risk assessments and regulatory compliance measures
- Regulatory compliance costs expected to increase due to phased EtO use restrictions and monitoring requirements over next 10 years
- Potential operational disruptions from future EtO emission controls pose business risk, reflecting heightened regulatory scrutiny
Risk Factors
- Regulatory/legal risk: Tariff and trade changes under the USMCA impacting exports and requiring compliance with evolving export duties and quotas
- Geopolitical/macro risk: Supply chain disruption risk from Russia-Ukraine war and Middle East conflict causing material raw material access issues in Europe
- Operational risk: Manufacturing facility risks include equipment failure, power outages, and compliance with environmental directives impacting profitability
- Competition risk: Facing competition from larger firms with superior R&D and production resources affecting market share and product demand
- Financial risk: Interest rate exposure from variable rates on five-year senior secured revolving credit agreement, including volatility in SOFR reference rates
Management Discussion & Analysis
- Revenue $1,037M, up 8.8% YoY; Human Nutrition & Health up $59.1M (9.9%), Animal Nutrition & Health up $16.1M (7.5%), Specialty Products up $8.2M (6.2%)
- Operating margin 20.2% vs 19.2%, earnings from operations $209.3M, up 14.4%; net earnings $154.8M, up 20.5%
- Best performing segment: Human Nutrition & Health earnings $153.9M, up 13.2%; worst: Animal Nutrition & Health earnings $18.7M, up 33.4% but lowest absolute profit
- Cash flow from operations $216.6M, capex $43.5M with $40-45M planned for 2026; share repurchases $107.6M, dividends paid $28.3M in 2025
- Management expects continued strong cash flow to fund growth and acquisitions; faces EU anti-dumping duties risk on choline chloride imports from China effective July 2025
AI summary of the BCPC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $283.997M, up 11.2% YoY from $255.467M
- Operating margin 20.9% vs 20.1%; gross margin 36.5% vs 36.4%
- Best segment Animal Nutrition & Health: sales $64.454M, up 15.0%; earnings $5.227M, up 48.7%
- Operating cash flow $86.772M, up 3.7%; cash declined to $63.174M from $74.570M
- Capital deployment: $44.484M share repurchases, $30.772M dividends, $17.138M capital investments
- Headwinds: geopolitical tensions, tariffs, energy, raw-material and freight-cost volatility; no material future cash-flow effect expected from tariffs
Risk Factors
- No material risk-factor changes since the December 31, 2025 Form 10-K
- Carried-forward regulatory and compliance risks unchanged from the annual filing
- Carried-forward operational and competitive risks unchanged from the annual filing
- Carried-forward financial and liquidity risks unchanged from the annual filing
AI summary of the BCPC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Balchem reported fiscal Q2 2026 earnings for the quarter ended June 30, 2026
- Full financial results and management commentary contained in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 2026 record results: sales $284.0M, up 11.2%; GAAP EPS $1.39, up from $1.17
- Adjusted EBITDA $77.9M, up 12.6%, with gross margin broadly stable at 36.5% versus 36.4%
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders re-elected David Fischer and Daniel Knutson to Class 3 director terms ending in 2029
- Knutson received stronger support, with 26,755,996 votes for versus Fischer’s 25,318,402
AI summaries of BCPC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BCPC
Don't miss the next BCPC filing
- Alerts as it files. A push when BCPC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BCPC, by share count.
- Ask anything. An AI agent that reads every BCPC filing and answers with sources.
BCPC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Boned Frederic | F | Feb 12, 2026 | 203 | $177.49 |
| Harris Theodore L | F | Feb 12, 2026 | 844 | $177.49 |
| van Gunsteren Job Leonard | F | Feb 12, 2026 | 58 | $177.49 |
| Bengtsson Carl Martin | F | Feb 12, 2026 | 302 | $177.49 |
| Miyata Hatsuki | F | Feb 12, 2026 | 181 | $177.49 |
| Reid Martin Luther | F | Feb 12, 2026 | 116 | $177.49 |
| Backus William A. | F | Feb 12, 2026 | 70 | $177.49 |
| Tignor Michael Brent | F | Feb 12, 2026 | 165 | $177.49 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $922.4M | $953.7M | $1.0B |
| Gross Profit | - | $336.2M | $370.6M |
| Operating Income | - | $182.9M | $209.3M |
| Net Income | $108.5M | $128.5M | $154.8M |
| Gross Margin | - | 35.3% | 35.7% |
| Op. Margin | - | 19.2% | 20.2% |
| Net Margin | 11.8% | 13.5% | 14.9% |
| Balance Sheet | |||
| Total Assets | $1.6B | $1.6B | $1.7B |
| Equity | - | $1.1B | $1.3B |
| ROE | - | 11.2% | 12.3% |
| Per Share | |||
| EPS | $3.35 | $3.93 | $4.75 |
| Cash Flow | |||
| Operating CF | - | $182.0M | $216.6M |
Source: XBRL data in BALCHEM CORP (BCPC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BCPC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 36 | $2.58B |
| Q1 2026 | 37 | $2.55B |
| Q4 2025 | 31 | $2.29B |
| Q3 2025 | 31 | $2.35B |
| Q2 2025 | 31 | $2.44B |
| Q1 2025 | 28 | $1.64B |
| Q4 2024 | 25 | $1.33B |
| Q3 2024 | 22 | $595.4M |
- BlackRock+122.9K (+3%)
- Goldman Sachs Group+103.6K (+62%)
- Two Sigma Investments+71.8K (+17%)
- Millennium Management+67.2K (+57%)
- Citadel Advisors LLC+40.9K (+198%)
- T. Rowe Price Group−97.0K (-47%)
- JPMorgan Chase & Co−85.3K (-20%)
- FMR LLC (Fidelity)−38.4K (-6%)
- Bank of America Corp−32.4K (-18%)
- D.E. Shaw & Co−31.4K (-78%)
- ASSOCIATED BANC-CORP−1.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BCPC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Jul 31, 2026 | - | Analysis | - |
| 10-Q | Jul 31, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 27, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 10-Q | Apr 30, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 30, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| SC 13G | Apr 28, 2026 | - | - | |
| 10-K | Feb 20, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 20, 2026 | - | - | |
| 8-K | Feb 19, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - |
Related Materials companies
- CC · Chemours CoChemicals & Allied Products
- ECVT · Ecovyst Inc.Chemicals & Allied Products
- FMC · Fmc CorpChemicals & Allied Products
- HUN · Huntsman CORPChemicals & Allied Products
- NGVT · Ingevity CorpChemicals & Allied Products
- IOSP · INNOSPEC INC.Chemicals & Allied Products
- AEM · Agnico Eagle Mines LtdGold and Silver Ores
- APD · Air ProductsIndustrial Inorganic Chemicals
BCPC SEC filings: frequently asked questions
Which institutions hold BCPC stock?
As of June 30, 2026, the largest BALCHEM CORP (BCPC) holders among the 13F filers tracked by SignalX were BlackRock ($838.7 million), Vanguard Portfolio Management LLC ($375.3 million), Vanguard Capital Management LLC ($244.2 million), State Street Corp ($216.5 million), Morgan Stanley ($141.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BCPC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BALCHEM CORP (BCPC) reported revenue of $1.0 billion (up 8.8% from FY2024) and net income of $154.8 million. Diluted EPS was $4.75. The figures come from the XBRL data in the 10-K.
What are the main risks in BCPC's latest 10-K?
In the 10-K filed February 20, 2026, BALCHEM CORP (BCPC) flagged: Regulatory/legal risk: Tariff and trade changes under the USMCA impacting exports and requiring compliance with evolving export duties and quotas. Geopolitical/macro risk: Supply chain disruption risk from Russia-Ukraine war and Middle East conflict causing material raw material access issues in Europe. (AI summary of the Risk Factors section.)
What did BCPC report in its latest 8-K?
BALCHEM CORP (BCPC) filed an 8-K on July 31, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Balchem reported fiscal Q2 2026 earnings for the quarter ended June 30, 2026.
What are the latest BCPC SEC filings?
BALCHEM CORP (BCPC) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on July 31, 2026, an 8-K current report on July 31, 2026 and a Form 4 insider filing on February 13, 2026.
What is BCPC's SEC CIK number?
BALCHEM CORP (BCPC)'s SEC Central Index Key (CIK) is 9326. EDGAR lists every BCPC filing under that number.
Ask anything about BCPC
The research agent reads BCPC's filings, financials, insider trades and 13F holders, then answers with sources.